Detalles de la búsqueda
1.
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.
Diabetes Ther
; 8(1): 101-114, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27943107
2.
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Diabetes Care
; 39(2): 231-41, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26358288
3.
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
Diabetes Care
; 35(11): 2174-81, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22933438
4.
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
Diabetes Care
; 30(6): 1608-10, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17372153
Resultados
1 -
4
de 4
1
Próxima >
>>